Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Triple-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Intravenous AMBTX-01 (Neridronate) for Treatment of Complex Regional Pain Syndrome Type 1 (CRPS-RISE)

NCT07210515 is registered in ClinicalTrials.gov with Ambros Therapeutics, Inc. as lead sponsor.

NCT NCT07210515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07210515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Triple-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Intravenous AMBTX-01 (Neridronate) for Treatment of Complex Regional Pain Syndrome Type 1 (CRPS-RISE)
Lead sponsor
Ambros Therapeutics, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
April 14, 2026
Completion date
January 31, 2028
Enrollment
270 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

complex regional pain syndrome type i